Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways

Hyperglycaemia-induced activation of the renin-angiotensin system (RAS) has been observed in normal and diabetic humans. Our main objective was to determine whether the mechanism involved a physical or metabolic effect of glucose. First, Sprague-Dawley rats of the CD strain were given sequential int...

Full description

Bibliographic Details
Main Authors: M Cecilia Lansang, Suzette Y Osei, Caroline Coletti, Janelle Krupinski, Norman K Hollenberg
Format: Article
Language:English
Published: SAGE Publications 2002-03-01
Series:Journal of the Renin-Angiotensin-Aldosterone System
Online Access:https://doi.org/10.3317/jraas.2002.003
_version_ 1797288725254766592
author M Cecilia Lansang
Suzette Y Osei
Caroline Coletti
Janelle Krupinski
Norman K Hollenberg
author_facet M Cecilia Lansang
Suzette Y Osei
Caroline Coletti
Janelle Krupinski
Norman K Hollenberg
author_sort M Cecilia Lansang
collection DOAJ
description Hyperglycaemia-induced activation of the renin-angiotensin system (RAS) has been observed in normal and diabetic humans. Our main objective was to determine whether the mechanism involved a physical or metabolic effect of glucose. First, Sprague-Dawley rats of the CD strain were given sequential intravenous (i.v.) doses of 0.01, 0.1, 1.0, and 3.0 mg/kg candesartan 30 minutes apart, in the presence of a continuous i.v. infusion of dextrose 20% in water (D20W). The 0.1 mg/kg dose produced a maximal renal blood flow (RBF) response and was used thereafter. Another set of animals then received an infusion of either normal saline (NS), dextrose 5% in water (D5W) or dextrose 20% in water (D20W) for 2 hours, followed by candesartan 0.1 mg/kg i.v. Finally, the response to candesartan 0.1 mg/kg i.v. during D20W infusion was compared with that during infusion of 2-deoxyglucose (2DG), a glucose analogue that competitively inhibits the glycolytic enzyme, hexokinase. RBF (electromagnetic flowmeter), blood pressure (BP), blood glucose, and urine glucose were monitored. There was no significant RBF response to candesartan on either NS (6.01±0.48 to 6.20±0.49 ml/minute/g kidney; p=0.216) or D5W (7.63±1.20 to 7.58±1.39 ml/minute/g kidney; p=0.965), whereas there was a significant response to D20W (6.64±0.59 to 7.46±0.67 ml/minute/g kidney; p=0.002). The RBF response was significantly enhanced by D20W compared with 2DG (change in RBF: 0.82±0.22 vs . -0.04±0.26; p=0.05), despite similar BP, blood glucose, and urine glucose. Glucose acts, at least in part, through intracellular utilisation to induce RAS activation, as manifested by an enhanced renal vascular response to an angiotensin II antagonist.
first_indexed 2024-03-07T18:53:40Z
format Article
id doaj.art-c61ced86037d4fc9bd2db72481050192
institution Directory Open Access Journal
issn 1470-3203
language English
last_indexed 2024-03-07T18:53:40Z
publishDate 2002-03-01
publisher SAGE Publications
record_format Article
series Journal of the Renin-Angiotensin-Aldosterone System
spelling doaj.art-c61ced86037d4fc9bd2db724810501922024-03-02T00:52:35ZengSAGE PublicationsJournal of the Renin-Angiotensin-Aldosterone System1470-32032002-03-01310.3317/jraas.2002.003Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathwaysM Cecilia LansangSuzette Y OseiCaroline ColettiJanelle KrupinskiNorman K HollenbergHyperglycaemia-induced activation of the renin-angiotensin system (RAS) has been observed in normal and diabetic humans. Our main objective was to determine whether the mechanism involved a physical or metabolic effect of glucose. First, Sprague-Dawley rats of the CD strain were given sequential intravenous (i.v.) doses of 0.01, 0.1, 1.0, and 3.0 mg/kg candesartan 30 minutes apart, in the presence of a continuous i.v. infusion of dextrose 20% in water (D20W). The 0.1 mg/kg dose produced a maximal renal blood flow (RBF) response and was used thereafter. Another set of animals then received an infusion of either normal saline (NS), dextrose 5% in water (D5W) or dextrose 20% in water (D20W) for 2 hours, followed by candesartan 0.1 mg/kg i.v. Finally, the response to candesartan 0.1 mg/kg i.v. during D20W infusion was compared with that during infusion of 2-deoxyglucose (2DG), a glucose analogue that competitively inhibits the glycolytic enzyme, hexokinase. RBF (electromagnetic flowmeter), blood pressure (BP), blood glucose, and urine glucose were monitored. There was no significant RBF response to candesartan on either NS (6.01±0.48 to 6.20±0.49 ml/minute/g kidney; p=0.216) or D5W (7.63±1.20 to 7.58±1.39 ml/minute/g kidney; p=0.965), whereas there was a significant response to D20W (6.64±0.59 to 7.46±0.67 ml/minute/g kidney; p=0.002). The RBF response was significantly enhanced by D20W compared with 2DG (change in RBF: 0.82±0.22 vs . -0.04±0.26; p=0.05), despite similar BP, blood glucose, and urine glucose. Glucose acts, at least in part, through intracellular utilisation to induce RAS activation, as manifested by an enhanced renal vascular response to an angiotensin II antagonist.https://doi.org/10.3317/jraas.2002.003
spellingShingle M Cecilia Lansang
Suzette Y Osei
Caroline Coletti
Janelle Krupinski
Norman K Hollenberg
Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways
Journal of the Renin-Angiotensin-Aldosterone System
title Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways
title_full Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways
title_fullStr Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways
title_full_unstemmed Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways
title_short Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways
title_sort hyperglycaemia induced intrarenal ras activation the contribution of metabolic pathways
url https://doi.org/10.3317/jraas.2002.003
work_keys_str_mv AT mcecilialansang hyperglycaemiainducedintrarenalrasactivationthecontributionofmetabolicpathways
AT suzetteyosei hyperglycaemiainducedintrarenalrasactivationthecontributionofmetabolicpathways
AT carolinecoletti hyperglycaemiainducedintrarenalrasactivationthecontributionofmetabolicpathways
AT janellekrupinski hyperglycaemiainducedintrarenalrasactivationthecontributionofmetabolicpathways
AT normankhollenberg hyperglycaemiainducedintrarenalrasactivationthecontributionofmetabolicpathways